View Clinical Trial (Medical Research Study)

A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients - NCT00725855-80262(Clinical Trial 234327)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Denver
State:  
CO
Zip Code: 80262
Conditions: Schizophrenia
Purpose: The purpose of this study is to evaluate the effects of nicotinic alpha-7 MEM 3454 on P50 sensory gating in patients with Schizophrenia. The hypothesis is that MEM 3454 will normalize the P50 ratio. Data produced in this study will provide useful information regarding the value of P50 as an efficacy biomarker, and provide evidence for the optimal dosing of MEM 3454 for additional P50 studies.
Study summary:
Criteria: Inclusion Criteria: - 1. Male or female subjects between 18and 55 years of age. - 2. Fluent in English, even if English is not the primary language. - 3. Able to provide informed consent. - 4. DSM IV-R primary diagnosis of schizophrenia (any subtype), assessed using a structured diagnostic interview (SCID CT). - 5. Few or no extra-pyramidal symptoms(EPS)at screening,defined as SAS < 6. - 6. Negative urine drug screen (UDS). - 7. Negative cotinine test. - 8. Clinically stable, as judged by the investigator, and in a non-acute phase for at least 12 weeks. At least one month on the same dose of antipsychotic medication. Exclusion Criteria: - Current risk of suicide, or history of suicidal behavior within the last 6 months. - Hospitalized for psychiatric symptoms in the past 3 months. - Other psychiatric diagnoses. - Substance abuse/dependence (other than nicotine or caffeine) within the last 6 months according to the SCID-CT. - Currently smoking, nicotine replacement therapy, smoking cessation medications or remedies, including Varenicline (Chantix). - Any medical condition, as judged by the Investigator, which may interfere with the subjects' participation in this study.
Study is available at: University of Colorado Health Sciences Center
Denver, CO 80262
United States

Primary Contact:
Ann Olincy, MD,
Email: ann.olincy@uchsc.edu
Phone: 303-315-5046
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.